# HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

**BOSTON, Mass., May 20, 2026** – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory pockets, today announced it will present preclinical data from the Company’s interferon regulatory factor 5 (IRF5) program in a poster presentation at the European Congress of Rheumatology (EULAR) 2026 taking place June 3-6, 2026, in London, UK.

Presentation details are as follows:

**Title:** Preclinical and Translational Assessment of Small Molecule IRF5 Inhibitors in Lupus-Relevant Systems

**Poster Number:** 1122

**Session:** Poster View VIII

**Location:** Poster View

**Session Date and Time:** Sat., Jun. 6, 10:15-11:15 BST

**About HotSpot Therapeutics, Inc.**

HotSpot Therapeutics, Inc. is a biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called “natural hotspots.” These pockets are decisive in controlling a protein’s cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology. The Company’s proprietary Smart Allostery™ platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots, as well as tailored pharmacology toolkits and bespoke chemistry to drive the rapid discovery of novel hotspot-targeted small molecules. Leveraging this approach, HotSpot is building a broad pipeline of novel allosteric therapies for the treatment of autoimmune diseases. To learn more, visit [www.hotspotthera.com](/content/site-root.html).

**HotSpot Investor & Media Contact:**

Natalie Wildenradt

nwildenradt@hotspotthera.com

## Connect with us

HotSpot Therapeutics, Inc.

One Design Center Place

Suite 19-600

Boston, MA 02210

[+1 (617) 758-8998](tel:+16177588998)

[info@hotspotthera.com](mailto:info@hotspotthera.com)